{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:30:59Z","timestamp":1789601459361,"version":"build-2803163510"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Hypereosinophilic syndrome (HES) and eosinophilic granulomatosis with polyangiitis (EGPA) both present with hypereosinophilia and organ damage induced by eosinophils. EGPA is also characterized by vasculitis and is associated with ANCA. Yet, discriminating HES from EGPA may be difficult in clinical practice as biomarkers to reliably differentiate between HES and EGPA are still lacking. In recent years, it has been demonstrated that targeting IL-5 is efficacious to treat HES and EGPA, and the use of anti-IL-5(R)-antibodies has become a mainstay of therapy in HES and these diseases. Nonetheless, it remains unclear whether anti-IL-5 strategies are sufficient to treat organ-threatening eosinophilic manifestations or vasculitic manifestations in EGPA.<\/jats:p>","DOI":"10.1093\/rheumatology\/keae608","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T09:18:38Z","timestamp":1741771118000},"page":"i92-i97","source":"Crossref","is-referenced-by-count":8,"title":["Highlights from the plenary session: eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1086-1034","authenticated-orcid":false,"given":"Julia U","family":"Holle","sequence":"first","affiliation":[{"name":"Rheumazentrum Schleswig-Holstein Mitte , Neum\u00fcnster,","place":["Germany"]},{"name":"Rheumazentrum Schleswig-Holstein Mitte , Kiel,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto","family":"Vaglio","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Unit, Meyer Children\u2019s Hospital IRCCS , Florence,","place":["Italy"]},{"name":"Department of Biomedical, Experimental and Clinical Sciences \u201cMario Serio\u201d, University of Florence , Florence,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"2025031209172576200_keae608-B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2025031209172576200_keae608-B2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/all.15544","article-title":"Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes","volume":"78","author":"Valent","year":"2023","journal-title":"Allergy"},{"key":"2025031209172576200_keae608-B3","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1002\/art.21250","article-title":"Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome","volume":"52","author":"Sinico","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2025031209172576200_keae608-B4","doi-asserted-by":"crossref","first-page":"632","DOI":"10.7326\/0003-4819-143-9-200511010-00006","article-title":"Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome","volume":"143","author":"Sabl\u00e9-Fourtassou","year":"2005","journal-title":"Ann Intern Med"},{"key":"2025031209172576200_keae608-B5","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.alit.2019.06.004","article-title":"Update on eosinophilic granulomatosis with polyangiitis","volume":"68","author":"Furuta","year":"2019","journal-title":"Allergol Int"},{"key":"2025031209172576200_keae608-B6","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1038\/s41467-019-12515-9","article-title":"Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status","volume":"10","author":"Lyons","year":"2019","journal-title":"Nat Commun"},{"key":"2025031209172576200_keae608-B7","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/art.41982","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis With Polyangiitis","volume":"74","author":"Grayson","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2025031209172576200_keae608-B8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.autrev.2016.09.018","article-title":"Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): a study of 157 patients by the Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires and the European Respiratory Society Taskforce on eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","volume":"16","author":"Cottin","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2025031209172576200_keae608-B9","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/annrheumdis-2012-201531","article-title":"A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients","volume":"72","author":"Moosig","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2025031209172576200_keae608-B10","first-page":"244","article-title":"A new index for distinguishing hypereosinophilic syndrome and antineutrophil cytoplasmic antibody-negative eosinophilic granulomatosis with polyangiitis","volume":"41","author":"Ahn","year":"2023","journal-title":"Asian Pac J Allergy Immunol"},{"key":"2025031209172576200_keae608-B11","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"2025031209172576200_keae608-B12","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"2025031209172576200_keae608-B13","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa070812","article-title":"Treatment of patients with the hypereosinophilic syndrome with mepolizumab","volume":"358","author":"Rothenberg","year":"2008","journal-title":"N Engl J Med"},{"key":"2025031209172576200_keae608-B14","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jaci.2020.08.037","article-title":"Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a phase III, randomized, placebo-controlled trial","volume":"146","author":"Roufosse","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"2025031209172576200_keae608-B15","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa2311155","article-title":"Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis","volume":"390","author":"Wechsler","year":"2024","journal-title":"N Engl J Med"},{"key":"2025031209172576200_keae608-B16","author":"Wechsler","year":"2024"},{"key":"2025031209172576200_keae608-B17","author":"Wechlser","year":"2024"},{"key":"2025031209172576200_keae608-B18","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJMoa1812185","article-title":"Benralizumab for PDGFRA-negative hypereosinophilic syndrome","volume":"380","author":"Kuang","year":"2019","journal-title":"N Engl J Med"},{"key":"2025031209172576200_keae608-B19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/art.41943","article-title":"Mepolizumab for eosinophilic granulomatosis with polyangiitis: a European multicenter observational study","volume":"74","author":"Bettiol","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2025031209172576200_keae608-B20","doi-asserted-by":"crossref","first-page":"e707","DOI":"10.1016\/S2665-9913(23)00243-6","article-title":"Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study","volume":"5","author":"Bettiol","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"2025031209172576200_keae608-B21","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard-2023-224624","article-title":"Benralizumab for eosinophilic granulomatosis with polyangiitis","volume":"82","author":"Cottu","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025031209172576200_keae608-B22","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jaip.2024.01.006","article-title":"Long-term effectiveness of benralizumab in eosinophilic granulomatosis with polyangiitis","volume":"12","author":"Nanzer","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025031209172576200_keae608-B23","author":"Mattioli","year":"2024"},{"key":"2025031209172576200_keae608-B24","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025031209172576200_keae608-B25","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025031209172576200_keae608-B26","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/acr2.11571","article-title":"Clinical benefit of mepolizumab in eosinophilic granulomatosis with polyangiitis for patients with and without a vasculitic phenotype","volume":"5","author":"Terrier","year":"2023","journal-title":"ACR Open Rheumatol"},{"key":"2025031209172576200_keae608-B27","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1182\/blood-2003-10-3620","article-title":"Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome","volume":"103","author":"Klion","year":"2004","journal-title":"Blood"},{"key":"2025031209172576200_keae608-B28","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.anai.2021.01.035","article-title":"Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis","volume":"126","author":"Manka","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025031209172576200_keae608-B29","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1136\/ard-2022-222776","article-title":"Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study","volume":"81","author":"Bettiol","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025031209172576200_keae608-B30","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1136\/ard-2023-224756","article-title":"Dupilumab for relapsing or refractory sinonasal and\/or asthma manifestations in eosinophilic granulomatosis with polyangiitis: a European retrospective study","volume":"82","author":"Molina","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025031209172576200_keae608-B31","first-page":"e27670","article-title":"Dupilumab-associated eosinophilic granulomatosis with polyangiitis","volume":"14","author":"Persaud","year":"2022","journal-title":"Cureus"},{"key":"2025031209172576200_keae608-B32","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12890-023-02415-6","article-title":"Eosinophilic granulomatosis with polyangiitis developed after dupilumab administration in patients with eosinophilic chronic rhinosinusitis and asthma: a case report","volume":"23","author":"Suzaki","year":"2023","journal-title":"BMC Pulm Med"},{"key":"2025031209172576200_keae608-B33","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/all.15934","article-title":"Eosinophilic granulomatosis with polyangiitis onset in severe asthma patients on monoclonal antibodies targeting type 2 inflammation: report from the European EGPA study group","volume":"79","author":"Caminati","year":"2024","journal-title":"Allergy"},{"key":"2025031209172576200_keae608-B34","author":"Rios-Garc\u00e9s","year":"2024"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/Supplement_1\/i92\/62374936\/keae608.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/Supplement_1\/i92\/62374936\/keae608.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T09:18:46Z","timestamp":1741771126000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/Supplement_1\/i92\/8069407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":34,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2025,3,12]]},"published-print":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae608","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,3,1]]}}}